Adult, adolescent & childn ≥10 yr w/ insufficiently controlled type 2 DM as an adjunct to diet & exercise, as monotherapy or in addition to other medicinal products for the treatment of DM. Prevention of major adverse CV events (CV death, non-fatal MI or non-fatal stroke) in adults w/ type 2 DM & at high CV risk, as an adjunct to standard of care therapy.
SC Initially 0.6 mg daily, increased to 1.2 mg after at least 1 wk. Increase from 1.2 mg to max dose of 1.8 mg after at least 1 wk to further improve glycemic control.
Should not be used in patients w/ type 1 DM or for the treatment of diabetic ketoacidosis. Not a substitute for insulin. Do not administer by IV or IM. Patients w/ CHF NYHA class IV; inflammatory bowel disease & diabetic gastroparesis; preexisting thyroid disease; history of pancreatitis. Severe renal impairment including end-stage renal disease; mild, moderate or severe hepatic impairment. Use of GLP-1 analogues has been associated w/ risk of acute pancreatitis; signs & symptoms of dehydration, including renal impairment & acute renal failure; increased risk of hypoglycemia when used in combination w/ sulfonylurea or a basal insulin. May affect ability to drive or operate machinery due to risk of hypoglycemia especially when used in combination w/ a sulfonylurea or basal insulin. Should not be used during pregnancy & lactation. Childn <10 yr & adolescent <18 yr. Elderly ≥75 yr.
Frequent monitoring of INR w/ warfarin or other coumarin derivatives. May decrease Cmax & delay median tmax of paracetamol, atorvastatin & OCs (eg, ethinylestradiol, levonorgestrel). May increase Cmax of griseofulvin. Reduced AUC, decreased Cmax & delayed tmax of digoxin & lisinopril.
Sign Out
